❗Let's close the gap: We still need your help to raise $40,000 by April 1. Donate now

Who owns the results of genetic testing?

Oct 16, 2018
Personal data from genetic tests has been used in drug development and research.
A visitor views a digital representation of the human genome in 2001 at the American Museum of Natural History in New York City.
Mario Tama/Getty Images

Who owns the results of genetic testing?

Oct 16, 2018
Personal data from genetic tests has been used in drug development and research.
A visitor views a digital representation of the human genome in 2001 at the American Museum of Natural History in New York City.
Mario Tama/Getty Images

Generic Viagra floods the market. Here’s how Pfizer is reacting

Jul 13, 2018
Pfizer hopes to run with its “little blue pill” as long as it can. That includes the time-honored strategy of launching its own generic.
Christopher Furlong/Getty Images

In the midst of a massive opioid crisis, hospitals are experiencing an opioid shortage

May 14, 2018
Drug shortages are nothing new in U.S. hospitals.
Illustration by Emily Judem/WGBH News. Photos courtesy of Benjamin Pennell and Massachusetts General Hospital.
 
Justin Sullivan/Getty Images

New class of generics could save consumers, insurers billions. FDA is moving carefully.

Jul 13, 2016
The European Union has some 20 "biosimilar" generics on the market; the US has one.
Pre-filled syringes of  the adalimumab biosimilar.  The biosimilar is used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis.
SAM PANTHAKY/AFP/Getty Images

What Brexit may mean for the pharmaceutical industry

Jun 28, 2016
Drug makers are raising concerns Brexit could delay regulatory approval, slow down funding for basic research
British drug makers could face new regulations and road blocks for research as the U.K. prepares to leave the EU. 
Chris Radburn/AFP/Getty Images

For public good, not for profit.

Valeant Pharmaceuticals and the dark side of capitalism

Jun 10, 2016
Investors' demands for more profits left patients with the choice to pay up or die.
Howard Schiller, interim CEO of Valeant Pharmaceuticals International, and Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, listen during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC.
BRENDAN SMIALOWSKI/AFP/Getty Images

Deals aimed at reining in costs of cancer drugs show promise

Jun 6, 2016
Some manufacturers are willing to tie drug price to performance.
Dr. Julie Brahmer (R) and Katie Thornton review PET (Positron Emission Tomography) scans of a patient being treated at the Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. 
Win McNamee/Getty Images

FTC fights against new strategy for delaying generics

Apr 1, 2016
FTC files case against drug maker for deals cut with two generic firms that extend its monopoly
John Moore/Getty Images